MGMT and central nervous system cancer: Interestingly, the risk score of glioma patients in the CGGA cohort was elevated not only in the age >50 years, more malignant type of 2016 WHO classification, higher grade, IDH wild type, and MGMT promoter unmethylated subgroups, but also in the male and 1p19q non-codel patients (Supplementary Figures 3A–G).